O estudo a que o(a) senhor(a) está sendo convidado a participar, visa definir a melhor maneira de ajustar o seu marca-passo.
Nós vamos pedir para o(a) senhor(a) fazer um exame, que é o ecocardiograma. Esse é um exame bem simples e sem dor que permite estudar como o seu coração está batendo. Durante o exame nós vamos fazer várias medidas no seu marca-passo visando ajustá-lo da melhor forma possível, para determinar sob qual programação o seu coração bate melhor. Este exame, o ecocardiograma é um exame de rotina para avaliar o seu coração, a única coisa diferente serão estes ajustes durante o exame.
É importante informar que este exame de ecocardiografia será um pouco mais demorado que um exame comum. No entanto, a realização deste exame não traz nenhum risco para o(a) senhor(a).
O beneficio que você terá em participar do estudo será este ajuste individualizado do seu marca-passo, no entanto, o(a) senhor(a) pode optar em não participar do estudo e, neste caso, o(a) senhor(a) seguirá normalmente seu tratamento.
Em qualquer etapa do estudo, o(a) senhor(a) terá acesso aos médicos responsáveis pelo estudo para tirar qualquer dúvida que possa vir a ter sobre o mesmo. Os médicos responsáveis pelo estudo são o Dr. José Carlos Pachón Mateos, do Instituto Dante Pazzanese de São Paulo e o Dr. Andrés Di Leoni Ferrari, que pode ser encontrado no endereço do Hospital São Lucas da PUCRS, Avenida Ipiranga, 6690 - sala 300 - telefone: 51-33205120 e 51- 33205100. Se você tiver alguma consideração ou dúvida sobre a ética da pesquisa, entre em contato com o Comitê de Ética em Pesquisa (CEP), Avenida Ipiranga, 6690, 3º- Andar, Hospital São Lucas da PUCRS - telefone: 51-3320-3345.
O(a) senhor(a) tem a garantia de poder sair do estudo a qualquer momento, sem qualquer prejuízo ao seu tratamento / acompanhamento no Hospital.
Todas as informações do(a) senhor(a) serão analisadas em conjunto com as de outros pacientes e o seu nome não será divulgado em nenhum momento e sob nenhuma hipótese.
O(a) senhor(a) também tem o direito de saber dos resultados do estudo sempre que estas informações estejam disponíveis.
O(a) senhor(a) não terá nenhuma despesa adicional para participar do estudo. O exame proposto de ecocardiograma será feito em um dia de sua avaliação de rotina no hospital. O(a) senhor(a) não terá qualquer compensação financeira por participar do estudo.
Nós só iremos usar as suas informações e os resultados do exame somente para este estudo.
Eu _____________________________________ (paciente ou responsável), fui informado dos objetivos da pesquisa de maneira clara e detalhada e esclareci minhas dúvidas. Sei que em qualquer momento poderei solicitar novas informações e modificar minha decisão se assim eu o desejar. O Dr. Andres Di Leoni Ferrari (pesquisador responsável) certificou-me de que todos os dados desta pesquisa serão confidenciais e terei liberdade de retirar meu consentimento de participação na pesquisa, em face destas informações.
_________________ ___________________ ____________ Assinatura do paciente Nome Data
_______________________ ___________________ _________ Assinatura do pesquisador Nome Data
Este formulário foi lido para __________________________________ (nome do paciente) em ____/____/___ (dd/mm/aa) enquanto eu estava presente.
_____________________ _________________ ________ Assinatura de testemunha Nome Data
10 REFERÊNCIAS
1. Ferrari ADL, Borges AP, Albuquerque LC, Sussenbach CP, Rosa PR da, Piantá RM, et al. Cardiac pacing induced cardiomyopathy: mith or reality sustained by evidence? Rev Bras Cir Cardiovasc. 2014;29(3):402-13. 2. Ferrari ADL, Borges AP, Pachón Mateos JC, Piantá RM, Bonato G,
Benedetti S. Características , benefícios e consequências dos algoritmos de minimização da estimulação do ventrículo direito por dispositivos de estimulação cardíaca. Relampa. 2015;28(2):59–70.
3. Alon U. How to choose a good scientific problem. Mol Cell. 2009;35(6):726–8.
4. Sweeney MO, Prinzen FW. Ventricular pump function and pacing: physiological and clinical integration. Circ Arrhythm Electrophysiol. 2008;1(2):127–39.
5. van Geldorp IE, Vanagt WY, Prinzen FW, Delhaas T. Chronic ventricular pacing in children: toward prevention of pacing-induced heart disease. Heart Fail Rev. 2011;16(3):305–14.
6. Pachón Mateos JC, Pachón Mateos EI, Pachón Mateos JC. Right ventricular apical pacing: the unwanted model of cardiac stimulation? Expert Rev Cardiovasc Ther. 2009;7(7):789–99.
7. Sweeney MO, Hellkamp AS, Ellenbogen K a, Greenspon AJ, Freedman R a, Lee KL, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107(23):2932–7.
8. Shukla HH, Hellkamp AS, James E a, Flaker GC, Lee KL, Sweeney MO, et al. Heart failure hospitalization is more common in pacemaker patients with sinus node dysfunction and a prolonged paced QRS duration. Heart Rhythm. 2005;2(3):245–51.
9. Nishióka SAD e cols. Preferência da condução ventricular intrínseca. In: Nishióka SAD, editor. Avaliação e programação dos marcapassos Saint Jude Medical: avaliação clínica e técnica. 1a. edição. Atheneu; 2017. p. 115–30.
10. Barold SS, Stroobandt RX SA. Cardiac Pacemakers and resynchronization step-by-Step. An illustrated guide. 2nd. Ed. Wiley- Blackwell Publishing Co. 2010.
11. Júnior AP, Ribeiro BC, Augusto J, Meneghini M, Sincos IC, Oliveira FF De, et al. Otimização do marcapasso na ressincronização cardíaca: importância da ecocardiografia. Relampa. 2012;25(2):107–16.
12. Pachón Mateos JC, Pachón Mateos EI, Carlos PMJ, Albornoz Vargas RN. Síndrome Ventricular do Marca-passo e Síndrome do QRS Largo”. In: Pachón Mateos JC, editor. Marca-passos, desfibriladores e ressincronizadores cardíacos – noções fundamentais para o clínico. 1a. Ed. Atheneu; 2014. p. 197–208.
13. Sweeney MO. Minimizing ventricular pacing to reduce atrial fibrillation in sinus node disease. N Engl J Med. 2007;17(1):57–8.
14. Gillis AM, Russo AM, Ellenbogen KA, Swerdlow CD, Olshansky B, Al- khatib SM, et al. HRS / ACCF Expert Consensus Statement on Pacemaker Device and Developed in partnership between the Heart Rhythm Society ( HRS ) and the American College of Cardiology. Heart Rhythm. 2012;6(26):1344–65.
15. Barold SS, Herweg B, Sweeney MO. Minimizing right ventricular pacing. Am J Cardiol. 2005;95(8):966–9.
16. Sweeney MO, Prinzen FW. A new paradigm for physiologic ventricular pacing. J Am Coll Cardiol. 2006;47(2):282–8.
17. Lund LH, Jurga J, Edner M, Benson L, Dahlström U, Linde C, et al. Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction. Eur Heart J. 2013;34(7):529–39.
18. Akerström F, Arias M a, Pachón M, Jiménez-López J, Puchol A, Juliá- Calvo J. The importance of avoiding unnecessary right ventricular pacing in clinical practice. World J Cardiol. 2013;5(11):410–9.
19. Cuervo DC, Manuel J, López R, Rebollo NP. Minimizar la estimulación en el ventrículo derecho : por qué , cuánto y en qué paciente. Una revisión clínica. Cuad Estimul. 2012;4(14):41–6.
20. Barold SS, Herweg B. Conventional and biventricular pacing in patients with first-degree atrioventricular block. Europace. 2012 Oct; 14 (10):1414–9.
21. Barold SS, Ilercil A, Leonelli F, Herweg B. First-degree atrioventricular block: Clinical manifestations, indications for pacing, pacemaker management & consequences during cardiac resynchronization. J Int Card Electrophysiol. 2006. p. 139–52.
22. Barold, S. Serge OI. Marked first-degree atrioventricular block: a new indication for cardiac pacing. Hell J Cardiol. 2002;43:162-71.
23. Bogdan S, Glikson M. Physiological pacing: a moving target? Eur Heart J. 2015;36(3):141–2.
24. Fidalgo Andrés ML, Tascón Pérez J, Pérez Álvarez L, Roda Nicolás J, Martínez Ferrer J, De Juan Montiel J. Estimulación cardiaca en situaciones diversas. Rev Esp Cardiol Supl. 2007;7:1-56.
25. Iliev II, Yamachika S, Muta K, Hayano M, Ishimatsu T, Nakao K, et al. Preserving normal ventricular activation versus atrioventricular delay optimization during pacing: the role of intrinsic atrioventricular conduction and pacing rate. Pacing Clin Electrophysiol. 2000;23(January):74–83.
26. Kenigsberg DN, Ellenbogen KA. Physiologic pacing: more answers, more questions. J Cardiovasc Electrophysiol. 2007 Sep;18(10):1037–8.
27. Klimczak A, Chudzik M, Zielińska M, Budzikowski AS, Lewek J, K.Wranicz J. Optimization of atrio-ventricular delay in patients with dual- chamber pacemaker. Int J Cardiol. 2010; 222–6.
28. Ledesma García C, García Calabozo R, Pastor Fuentes A. Selección del modo de estimulación en las bradiarritmias. Controversias sobre la indicación del modo AAI o el modo DDD en la enfermedad del nódulo sinusal y sobre la utilización del modo VDD en el bloqueo auriculoventricular. Rev Esp Cardiol Supl. 2007 Jan;7(7):69G–81G.
29. Mani H, Shirayama T, Suzaki Y, Sakatani T, Sakamoto T, Yamamura M, et al. Clinical significance of preserving spontaneous QRS wave in the therapy of DDD pacing for sick sinus syndrome. Pacing Clin Electrophysiol. 2004 Sep;27(9):1212–6.
30. Manisty CH, Al-Hussaini A, Unsworth B, Baruah R, Pabari P a, Mayet J, et al. The acute effects of changes to AV delay on BP and stroke volume: potential implications for design of pacemaker optimization protocols. Circ Arrhythm Electrophysiol. 2012;5(1):122–30.
31. Padeletti L, Pontecorboli G, Michelucci A, Mond HG. AAIR or DDDR pacing for sick sinus syndrome: the physiologic conundrum. Europace. 2012;14(6):781–2.
32. Reynolds DW, Murray CM. New concepts in physiologic cardiac pacing. Current Cardiology Reports. 2007;351-7.
33. Stierle U, Kruger D, Vincent AM, Mitusch R, Giannitsis E, Wiegand UPJ. An optimized AV delay algorithm for patients with intermittent atrioventricular conduction. Pacing Clin Electrophysiol. 1998;21(5):1035- 43.
34. Vardas PE, Simantirakis EN, Parthenakis FI, Chrysostomakis SI, Skalidis EI, Zuridakis EG. AAIR versus DDDR pacing in patients with impaired sinus node chronotropy: an echocardiographic and cardiopulmonary study. Pacing Clin Electrophysiol. 1997;20(7):1762–8.
35. Alonso A, Chen LY. PR interval, P-wave duration, and mortality: New insights, additional questions. Heart Rhythm. 2014;11(1):99–100.
36. Kwok CS, Rashid M, Beynon R, Barker D, Patwala A, Morley-Davies A, et al. Prolonged PR interval, first-degree heart block and adverse cardiovascular outcomes: a systematic review and meta-analysis. Heart. 2016;102(9):672–80.
37. Akrawinthawong K, Mehdirad AA. Pacemaker indication in first-degree AV block patients: Factors beyond the PR interval/HR slope. Int J Cardiol. 2016;203:1151.
38. Laurent G, Eicher JC, Wolf JE. First-degree atrioventricular block and pseudopacemaker syndrome. Arch Cardiovasc Dis. 2013;106(12):690– 3.
39. Barold SS, Israel CW. The changing landscape of cardiac pacing. J Mol Cell Cardiol. 2015;84(December 2014):32–8.
40. Garillo R, Moreno Alvarez M. Marcapasos cardiacos. Estimulación desde el ventrículo derecho: beneficios y perjuicios a la luz de la experiencia actual. Rev Costarric Cardiol. 2011;13(1):19–22.
41. Tracy CM, Epstein AE, Darbar D, Dimarco JP, Dunbar SB, Estes NAM, et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. J Am Coll Cardiol. 2012;60(14):1297- 313.
42. Fuganti CJ, Melo CS, Moraes Jr AV, Pachón-Mateos JC, Pereira WL, Galvão Filho SS, et al. Diretrizes Brasileiras de Dispositivos Cardíacos Eletrônicos Implantáveis do Departamento de Estimulação Cardíaca Arti fi cial (DECA) da Sociedade Brasileira de Cirurgia Cardiovascular (SBCCV). Relampa. 2015;28(2 Supl):S1–62.
43. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt O-A, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association. Eur Heart J. 2013;34(29):2281–329.
44. Lamas G a, Lee KL, Sweeney MO, Silverman R, Leon A, Yee R, et al. Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med. 2002;346(24):1854–62.
45. Sweeney MO, Ellenbogen K a, Tang ASL, Johnson J, Belk P, Sheldon T. Severe atrioventricular decoupling, uncoupling, and ventriculoatrial coupling during enhanced atrial pacing: incidence, mechanisms, and implications for minimizing right ventricular pacing in ICD patients. J Cardiovasc Electrophysiol. 2008;19(11):1175–80.
46. Gaztañaga L, Marchlinski FE, Betensky BP. Mecanismos de las arritmias cardiacas. Rev Esp Cardiol. 2012;65(2):174–85.
47. Castro AM, Clara S, Clara V. Revisión ADE. Bases electrofisiológicas de la estimulación cardíaca. 2009;1(4).
48. Pastore CA, Pinho C, Germiniani H, Samesima N, Mano R, et al. Diretrizes da Sociedade Brasileira de Cardiologia sobre análise e emissão de laudos eletrocardiográficos (Sumário); Arq Bras Cardiol. 2009;93(Supl.2):1-19).
49. Siu C-W, Wang M, Zhang X-H, Lau C-P, Tse H-F. Analysis of ventricular performance as a function of pacing site and mode. Prog Cardiovasc Dis. 2008;51(2):171–82.
50. Montanez A, Hennekens CH, Zebede J, Lamas GA. Pacemaker mode selection: the evidence from randomized trials. Pacing Clin Electrophysiol. 2003;26(May):1270–82.
51. Fang F, Sanderson JE, Yu CM. Should all patients with heart block receive biventricular pacing? All heart block patients with a pacemaker indication should receive biventricular pacing: one move, double the gains? Circ Arrhythmia Electrophysiol. 2015;8(3):722–9.
52. Melo CS De, Pereira CA, Garcia FS, Cristina T, Roberto W, Baccaglini C, et al. Código de nomenclatura de marcapassos e cardiodesfibriladores. Relampa. 2011;24(4):271–6.
53. Lorga A, Sp F, Alves A, Ba F, Roberto Á, Barros C, et al. Diretrizes Brasileiras de Dispositivos Cardíacos Eletrônicos Implantáveis (DCEI). 2007;89(6):210–38.
54. Montiel JDJ, Diarte EC, Crepo EP, Barcos AMLPP. Consecuencias hemodinámicas de la estimulación cardiaca. Cuad Técnicos. 2004;(9):1- 29.
55. Ufberg JW, Clark JS. Bradydysrhythmias and atrioventricular conduction blocks. Emerg Med Clin North Am. 2006;24(1):1–9.
56. Neto JE, Junior HL de B. Doença do nó sinusal e bloqueios atrioventriculares. In: Pereira de Magalhães L, Benchimol Saad E, editors. Estimulação cardíaca artificial na prática clínica. 1a ed. Atheneu; 2014. p. 29–50.
57. Corcoran SJ, Davis LM. Cardiac implantable electronic device therapy for bradyarrhythmias and tachyarrhythmias. Heart Lung Circ. 2012;21(6– 7):328–37.
58. Semelka M, Gera J, Usman S. Sick sinus syndrome: a review. Am Fam Physician. 2013;87(10):691–6.
59. Mond HG, Proclemer A. The 11th world survey of cardiac pacing and implantable cardioverter-defibrillators: Calendar year 2009 - A world society of Arrhythmia’s project. Pacing Clin Electrophysiol. 2011;34(8):1013–27.
60. Pachón Mateos EI, Pachón Mateos JC. Disfunção do Nó Sinusal. Cap.2. Bases fisiopatológicas das arritmias cardíacas; série clinicas brasileiras de arritmias cardíacas: Ano 1, Volume 1. Eds: Martinelli Fo Martino; Zimerman Leandro I. 2008. p. 11–26.
61. Jose C. Pachon M, Enrique I. Pachon M, Juan C. Pachon M, Tasso J. Lobo, Maria Z. Pachon, Remy N.A. Vargas ADJ. Cardioneuroablation” – new treatment for neurocardiogenic syncope, functional AV block and sinus dysfunction using catheter RF-ablation. Europace. 2005;7(1):1–13.
62. Pachon M JC, Pachon M EI, Cunha Pachon MZ, Lobo TJ, Pachon M JC, Santillana P TG. Catheter ablation of severe neurally meditated reflex (neurocardiogenic or vasovagal) syncope: cardioneuroablation long-term results. Europace. 2011;13(9):1231–42.
63. Pachón-mateos JC, Pereira WL, Duarte W, Junior B, Mateos CP, Indalécio E, et al. RBM - Registro Brasileiro de Marcapassos , Ressincronizadores e Desfibriladores. Relampa. 2013;26(1):39–49.
64. Bang CN, Okin PM. First-degree AV block may not be so benign after all. J Hypertens. 2014;7:281.
65. Uhm JS, SHim J, Wi J, Mun HS, Park JPSH, et al. First-degree atrioventricular block is associated with advanced atrioventricular. J Hypertens. 2014;32(5):1154.
66. Cheng S, Keyes MJ, Larson MG, McCabe EL, Newton-Cheh C, Levy D, et al. Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block. JAMA. 2009;301(24):2571–7.
67. Holmqvist F, Daubert JP. First-Degree AV. Block - an entirely benign finding or a potentially curable cause of cardiac disease? Ann Noninvasive Electrocardiol. 2013;18(3):215–24.
68. Nikolaidou T, Ghosh JM, Clark AL. Outcomes related to first-degree atrioventricular block and therapeutic implications in patients with heart failure. JACC Clin Electrophysiol. 2016;2(2):181–92.
69. Aro AL, Anttonen O, Kerola T, Junttila MJ, Tikkanen JT, Rissanen H a, et al. Prognostic significance of prolonged PR interval in the general population. Eur Heart J. 2014;35(2):123–9.
70. Nelson W. Abnormalities of impulse formation and conduction. Card Electrophysiol Clin. 2012;4(4):469–78.
71. Crisel RK, Farzaneh-Far R, Na B, Whooley MA. First-degree atrioventricular block is associated with heart failure and death in persons with stable coronary artery disease: data from the Heart and Soul Study. Eur Heart J. 2011;32(15):1875–80.
72. Cheng M, Lu X, Huang J, Zhang S, Gu D. Electrocardiographic PR prolongation and atrial fibrillation risk: a meta-analysis of prospective cohort studies. J Cardiovasc Electrophysiol. 2015 Jan;26(1):36-41 73. Janosik DL, Pearson AC, Buckingham TA, Labovitz AJ, Redd RM, The
W, et al. The hemodynamic benefit of differential atrioventricular delay intervals for sensed and paced atrial events during physiological pacing. J Am Coll Cardiol JACC. 1989;14(August):499–507.
74. Nielsen JC, Thomsen PEB, Højberg S, Møller M, Vesterlund T, Dalsgaard D, et al. A comparison of single-lead atrial pacing with dual- chamber pacing in sick sinus syndrome. Eur Heart J. 2011;32:686–96.
75. Nielsen JC, Thomsen PEB, Højberg S, Møller M, Riahi S, Dalsgaard D, et al. Atrial fibrillation in patients with sick sinus syndrome: the association with PQ-interval and percentage of ventricular pacing. Europace. 2012;14(5):682–9.
76. Holmqvist F., Hellkamp AS., Lee KL., Lamas GA. DJ. Adverse effects of first-degree av-block in patients with sinus node dysfunction: data from the mode selection trial. Pacing Clin Electrophysiol. 2014; 37(9):1111-9. 77. Biffi M, Melissano D, Rossi P, Kaliska G, Havlicek A, Pelargonio G, et al. The OPTI-MIND study: A prospective, observational study of pacemaker patients according to pacing modality and primary indications. Europace. 2014;16(5):689–97.
78. Sweeney MO. Algorithms for Minimizing Right Ventricular Pacing. In: Al- Ahmad, Amin, Ellenbogen Kenneth A, Natale Andrea WPJ, editor. Pacemakers and implantable cardioverter defibrillators - an expert’s manual. 1st. Cardiotext; 2010. p. 79–115.
79. Auricchio A, Ellenbogen KA. Reducing ventricular pacing frequency in patients with atrioventricular block. Circ Arrhythmia Electrophysiol. 2016;9(9):1–10.
80. Barold SS. Permanent single chamber atrial pacing is obsolete. Pacing Clin Electrophysiol. 2001;24(3):271–5.
81. Kirkfeldt RE, Andersen HR, Nielsen JC. System upgrade and its complications in patients with a single lead atrial pacemaker: Data from the DANPACE trial. Europace. 2013;15:1166–73.
82. Fidalgo Andrés ML, González Rebollo JM, Cañon A, Perez A, Brea C, F. VF. Programación del intervalo AV en dispositivos implantables bicamerales. Cuad Estimul. 2014;7(21):55–60.
83. Gillis AM, Pürerfellner H, Israel CW, Sunthorn H, Kacet S, Anelli-Monti M, et al. Reducing unnecessary right ventricular pacing with the managed ventricular pacing mode in patients with sinus node disease and AV block. Pacing Clin Electrophysiol. 2006;29(July):697–705.
84. Sweeney MO, Ellenbogen K a., Miller EH, Sherfesee L, Sheldon T, Whellan D. The Managed Ventricular pacing versus VVI 40 Pacing (MVP) Trial: Clinical background, rationale, design, and implementation. J Cardiovasc Electrophysiol. 2006;17:1295–8.
85. Barold SS. Indications for permanent cardiac pacing in first-degree AV block: class I, II, or III? Pacing Clin Electrophysiol. 1996:747–51.
86. Ahmed M, Gorcsan J, Marek J, Ryo K, Haugaa K, R Ludwig D, et al. Right ventricular apical pacing-induced left ventricular dyssynchrony is associated with a subsequent decline in ejection fraction. Heart Rhythm. 2014;11(4):602–8.
87. Cazeau S, Bordachar P, Jauvert G, Lazarus A, Alonso C, Vandrell MC, et al. Echocardiographic modeling of cardiac dyssynchrony before and during multisite stimulation: a prospective study. Pacing Clin Electrophysiol. 2003;26:137-43.
88. Antonini L, Pasceri V, Aiello A SM. Atrioventricular asynchrony and pacing. G Ital Cardiol. 2010;11:28–34.
89. De Juan Montiel J, Olagüe De Ros J, Morell Cabedo S, García Bolao I. Seguimiento del paciente con marcapasos. Disfunciones del sistema de estimulación. Efectos de indicación o programación incorrecta: Síndrome de marcapasos. Rev Esp Cardiol Supl. 2007;7:126-44. 90. Poghosyan HR, Jamalyan S V. Comparison of pacing algorithms to avoid
unnecessary ventricular pacing in patients with sick sinus node syndrome: A single-centre, observational, parallel study. Europace. 2012;14:1483–9.
91. Bode F, Wiegand U, Katus HA, Potratz J. Inhibition of ventricular stimulation in patients with dual chamber pacemakers and prolonged AV conduction. Pacing Clin Electrophysiol. 1999;22(10):1425–31.
92. Ishikawa T, Sumita S, Kosuge M, Giese C, Markowitz T, Tsunoda S, et al. Reducing ventricular pacing in sinus node dysfunction. Int Heart J. 2007;48:323–36.
93. Chwyczko T, Dąbrowski R, Maciąg A, Sterliński M, Smolis-Bąk E, Borowiec A, et al. Potential prevention of pacing-induced heart failure using simple pacemaker programming algorithm. Ann Noninvasive Electrocardiol. 2013;18(4):369–78.
94. Fröhlig G, Gras D, Victor J, Mabo P, Galley D, Savouré A, et al. Use of a new cardiac pacing mode designed to eliminate unnecessary ventricular pacing. Europace. 2006;8(2):96–101.
95. García Calabozo R. Temas de actualidad en estimulación cardíaca. Rev Esp Cardiol Supl. 2005;5(1):66A–76A.
96. Santini M, Ricci R. Is AAI or AAIR still a viable mode of pacing? Pacing Clin Electrophysiol. 2001;24(3):276–81.
97. Stockburger M, Boveda S, Moreno J, Da Costa A, Hatala R, Brachmann J, et al. Long-term clinical effects of ventricular pacing reduction with a changeover mode to minimize ventricular pacing in a general pacemaker population. Eur Heart J. 2015;36(3):151–7.
98. Akerström F, Pachón M, Puchol A, Jiménez-López J, Segovia D, Rodríguez-Padial L, et al. Chronic right ventricular apical pacing: adverse effects and current therapeutic strategies to minimize them. Int J Cardiol. 2014;173(3):351–60.
99. Chen S, Chen K, Tao Q, Zheng L, Shen F, Wu S, et al. Reduction of unnecessary right ventricular pacing by managed ventricular pacing and search AV algorithms in pacemaker patients : 12-month follow-up results of a randomized study. Europace. 2014;16:1595–602.
100. Nielsen JC, Kristensen L, Andersen HR, Mortensen PT, Pedersen OL, Pedersen AK. A randomized comparison ofatrial and dual-chamber pacing in177 consecutive patients with sick sinus syndrome. J Am Coll Cardiol. 2003;42(4):614–23.
101. Riahi S, Nielsen JC, Hjortshoj S, Thomsen PEB, Hojberg S, Moller M, et al. Heart failure in patients with sick sinus syndrome treated with single lead atrial or dual-chamber pacing: No association with pacing mode or right ventricular pacing site. Europace. 2012;14:1475–82.
102. Botto GL, Ricci RP, Bénézet JM, Nielsen JC, De Roy L, Piot O, et al. Managed ventricular pacing compared with conventional dual-chamber pacing for elective replacement in chronically paced patients: results of the Prefer for Elective Replacement Managed Ventricular Pacing randomized study. Heart Rhythm. 2014;11(6):992–1000.
103. Healey JS, Toff WD, Lamas G a, Andersen HR, Thorpe KE, Ellenbogen K a, et al. Cardiovascular outcomes with atrial-based pacing compared with ventricular pacing: meta-analysis of randomized trials, using individual patient data. Circulation. 2006;114(1):11–7.
104. Barold SS, Stroobandt RX. Pacemaker-mediated tachycardia initiated by an atrioventricular search algorithm to minimize right ventricular pacing. J Electrocardiol. 2012;45(3):336–9.
105. Mulpuru SK, Madhavan M, McLeod CJ, Cha Y-M, Friedman PA. Cardiac pacemakers : function , troubleshooting and management. J Am Coll Cardiol JACC. 2017;69(2):189–210.
106. Barold SS. Repetitive reentrant and non-reentrant ventriculoatrial synchrony in dual chamber pacing. Clin Cardiol. 1991;14:754–63.
107. Dennis MJ, Sparks PB. Pacemaker mediated tachycardia as a complication of the autointrinsic conduction search function. Pacing Clin Electrophysiol. 2004;27:824–6.
108. Burri H, Deharo J-C, Israel CW. The European Heart Rhythm Association book of pacemaker, ICD, and CRT troubleshooting. 1st ed. Burri H, Deharo JC, Israel CW, editors. Oxford University Press; 2016. 1-290 p. 109. Barold SS, Levine PA. Pacemaker repetitive nonreentrant ventriculoatrial